Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OligoG

Next Previous
Drug Profile

OligoG

Alternative Names: Alginate oligosaccharide (G-block) fragment; Oligo-COPD-10/20(1); OligoG CF-5/20; OligoG-COPD-5/20; Oligosaccharide nanotherapeutic - AlgiPharma

Latest Information Update: 05 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Norwegian university of science and technology
  • Developer AlgiPharma
  • Class Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Bronchodilators; Oligosaccharides
  • Mechanism of Action Bacterial growth inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis
  • No development reported Bacterial infections; Chronic obstructive pulmonary disease; Mycoses

Most Recent Events

  • 28 Oct 2024 AlgiPharma terminates a phase-IIb trial in Cystic fibrosis in Australia (Inhalation) due to futility (NCT03822455)
  • 23 Jul 2022 No development reported - Phase-II for Cystic fibrosis in Australia (Inhalation)
  • 27 Jun 2022 AlgiPharma AS withdraws prior to enrolment a phase II/III clinical trials in Cystic fibrosis (In children, In adults, In the elderly) in Germany due to not feasible (Inhalation) (NCT03698448) (EudraCT2018-000378-30)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top